Introduction
In 1952, acting upon the suggestions of Laborit, Delay demonstrated that chlorpromazine was effective in the treatment of psychosis (8) . Since then, pharmacological and clinical observations have shown that it is an effective antiemetic drug (11) which causes a Parkinson-like syndrome in patients. Based on these observations, laboratory tests were developed for the selection of drugs with possible antischizophrenic activity. These tests included the measurement of cataleptogenic activity and protection against apomorphine or amphetamine-induced stereotypies (15) . Moreover, chlorpromazine and other neuroleptics were shown to increase the turnover of dopamine in the brain, an effect explained to be due to feedback activation of presynaptic dopaminergic neurons caused by blockade of striatal dopamine receptors (1, 9, 20) .
Thus emerged the DA hypothesis of schizophrenia, explaining both the extrapyramidal side effects and the antischizophrenic activity of neuroleptic drugs (13, 17) . Blockade of dopamine receptors in animals results in catalepsy and protection against apomorphine-induced stereotypies and vomiting. In man, psychotic symptoms are controlled and a Parkinson-like syndrome develops. Extrapyramidal effects were considered indispensable for an antipsychotic agent and, indeed, some clinicians considered the therapeutic dosage level as equivalent to the dose required to produce extrapyramidal side effects.
The advent of clozapine seems to pose a challenge to many of the basic tenets of the dopamine hypothesis of schizophrenia. In this paper we review the results of our clinical evaluations and discuss some of the theoretical and practical implications.
Clozapinet is a dibenzodiazepine derivative with antipsychotic properties. It differs in a number of ways from the existing neuroleptics of the phenothiazine, thioxanthine and butyrophenone types: A) It is a tricylic compound with an asymmetric seven membered central ring. The chemical structure:
8-chloro-ll-(4-methyl-lpiperazinyl)-5H-dibenzo (b,e) (l,4) diazepine is related to the anti-depressant dibenzepinett and is similar to two other new compounds of the classical neuroleptic type, loxapinettt and metiapinej ( Figure  1) little acnvity in those tests considered specific for drugs with antipsychotic properties. It has no cataleptogenic effect and no antagonistic effect against apomorphineinduced stereotypies in experimental animals (26) . It has only weak antagonistic effect against amphetamine-induced stereotypies (26) . Furthermore, it inhibits conditioned avoidance behaviour only at doses producing severe sedation (Table I) . C) Clinically, clozapine has been reported to have a good antipsychotic effect and virtually no extrapyramidal side effects (18, 22, 23) .
A clinical study was carried out to evaluate the antipsychotic effects of clozapine in chronic schizophrenic patients and to assess adverse reactions produced by the drug.
Materials and Methods

Design
A 12-week uncontrolled clinical trial with a fixed-changing drug dosage schedule was carried out with nineteen chronic schizophrenic patients. There was a two-week placebo washout period at both the pre-treatment and posttreatment phase, for a total study period of 16 weeks.
Experimental population
Nineteen chronic schizophrenic patients, 16 male and 3 female, who had been hospitalized for more than two years at the Douglas Hospital in Verdun, Quebec, were included in the trial. Their mean age was 39.3 years (range 20 to 59) and their mean length of hospitalization was 12.0 years (range 3 to 32).
Inclusion criteria were: clinical diagnosis of schizophrenia by the WHO classification (ten patients were diagnosed as paranoid, six as hebephrenic, and three as undifferentiated); length of hospitalization (more than two years); and a minimum score of 30 on the Brief Psychiatric Rating Scale (BPRS) after two weeks of placebo washout. All patients were physically healthy and showed no evidence of CNS involvement.
Experimental procedure
Clozapine was supplied in the form of 25 and 100 mg capsules; the only other psychotropic drugs permitted during the trial were chloral hydrate and haldol as necessary for night-time sedation and behavioural control respectively. After a two-week placebo washout period each patient was initiated on 25 mg of clozapine three times daily, which was increased to 100 mg three times daily on the fourth day. The dosage was raised to 400 mg and then 600 mg daily during the second and third weeks respectively, and the maximum daily dosage of 800 mg was administered for the final eight weeks. This was again followed by a two-week post-drug placebo period. Dosage adjustment was flexible and was based on symptomatic changes as well as adverse reactions.
Assessment procedures
Each patient was interviewed a total of nine times, with a BPRS being completed at each psychiatric assessment. This occurred at the end of the pre-treatment washout, at the end of the first, second, third and fifth, seventh, tenth and twelfth week of drug administration, and finally at the end of the post-treatment washout period. Concurrently with the BPRS, the Nurses' Observation Scale for In-patient Evaluation (NOSIE) was completed by the patient's nurse. The Dosage Record and Treatment Emergent Symptoms Scale (DOTES) was completed at the same intervals as the BPRS and whenever an adverse reaction or dosage change occurred.
Demographic data were recorded on the Personal Data Inventory (POI). The Clinical Global Impression Scale (CGI) was completed at the end of the pre-treatment placebo washout period and after the twelfth week of drug administration.
The Brief Physical Routine (blood pressure, pulse rate and weight) was carried out at the same time as the BPRS. Clozapine has been reported to induce a hyperthermia (26) and for this reason body temperature was recorded at the end of the pre-treatment washout period, twice daily for the first four weeks of drug administration, and then weekly for the remainder of the clinical trial. Electrocardiograms were taken prior to admission to the study, and at the end of the fourth and twelfth week of the active drug phase.
A comprehensive battery of laboratory tests was carried out prior to admission to the clinical trial, at the end of the pre-treatment placebo washout period, following I, 2, 3, 5, 8, and 12 weeks of drug administration, and at the end of post-treatment placebo washout period. This consisted of hemoglobin, hematocrit, white blood count (total and differential), SGOT, SGPT, alkaline phosphatase, serum bilirubin (total and direct) and urinalysis.
Results
Clinical observations
The BPRS was analysed with respect to the total score, 18 items, and five derivative factors. Figure 2 demonstrates the decrease in the mean total BPRS score over 12 weeks of drug administration. Comparison of scores during the pre-drug period with those during the drug administration period shows improvement at the p<O.OOl level of significance (analysis of variance). The maximum therapeutic effect was seen to occur at the maximum mean daily dosage of 647.5 mg. Figure 3 presents the 18 individual items: fourteen items showed statistically significant (p < 0.05 -< 0.001) improvement during the active drug phase. The remaining four items, although non-significant, tended towards improvement during clozapine treatment. No item showed deterioration in more than a single patient. The mean BPRS factor scores, namely, Thinking Disorder, Activation, Hostile-Suspiciousness, Anergia, and Anxietydepression, all showed improvement (p < 0.001) with drug treatment (Figure 4 ).
The analyses of the NOSIE factors showed only one factor -Social Interestapproaching significance to indicate improvement during the active drug period (p < 0.10). The total score, as well as two other factors, social competence and personal neatness, tended to show improve-ment with drug administration but were not significant.
Both items on the COl (Degree of Mental Illness and the Change in Condition) showed a decline indicative of improvement with clozapine over the baseline placebo period. Table II lists Nine patients complained of hypersalivation; often this manifested itself by excessive saliva on the pillow-case. Weight gain occurred in seven patients; the pre-drug versus post-drug change for the group being significant at the p < .01 level. One patient gained 27 pounds. Transient hypotensive episodes were present in five patients, but at no time did this necessitate dosage change. Four patients reported constipation of a moderate degree, Hyperthermia was not observed.
Side effects
No extrapyramidal side effects were noted with the exception of three cases of mild tremor of the hands and one patient who complained of sporadic muscle spasm in the arm.
Laboratory data
No electrocardiographic changes were identified. There were sporadic fluctuations within the normal range in the total white cell count, but no abnormality related to the drug administration was encountered during the study.
Five patients exhibited abnormalities in the liver function tests, particularly elevation of the transaminase enzymes. One patient showed an isolated elevation of the bilirubin. In two of these patients there was some indication of a relationship between the elevated SGOT, SGPT and drug dosage. 
Discussion
Our results confirm the findings of other authors who reported good antipsychotic effects of clozapine in a great number of patients without observing major disturbances in extrapyramidal functions. From the clinical point of view there was no relationship between antipsychotic efficacy and extrapyramidal side effects. Burki et al., (7) extend this lack of relationship further to DA receptor blockade and argue that dopamine hypothesis of schizophrenia should be abandoned. They point out that clozapine would not have qualified as a potential neuroleptic if the usual criteria of selecting antipsychotic drugs were to be applied (26) .
Biochemical evidence shows that clozapine, in common with classical neuroleptics, affect the dopaminergic system in the striatum (4, 21) . However, its mechanism of action differs from that of the classical neuroleptics in that it increases striatal homo vanillic acid (HVA) and dihydroxyphenyl acetic acid only in very high doses. Moreover, it increases striatal DA content unlike the classical neuroleptics which decrease it (6) .
Other findings, cited against DA receptor blocking action of clozapine are: (i) lack of tolerance in experimental animals to the striatal HVA increasing action, on repeated administration of clozapine, and lack of cross tolerance to the HVA increasing action of haloperidol and loxapine following pre-treatment with clozapine (7); (ii) its failure (on pre-treatment) to augment apomorphine-induced turning behaviour in rats with unilateral striatal lesions and (iii) its negligible effect on prolactin secretion (7) .
In view of the potent antischizophrenic action of clozapine it would appear that DA-receptor blockade is not essential for antipsychotic activity in man. Some studies have shown, however, that clozapine does have an antidopaminergic action.
Fog (12) has demonstrated that direct administration of clozapine in the striatum does produce catalepsy in experimental animals.
Recently, evidence has been presented to the effect that DA sensitive adenylate cyclase may be part of, or identical to, the central "DA-receptor" (10) . Low concen_ tration of DA or apomorphine stimulate adenyl ate cyclase activity and this effect is blocked by low concentrations haloperidol or chlorpromazine (17) and also by clozapine (16, 19) . This indicates that clozapine has potent DA blocking properties.
Some explanations have been advanced to reconcile these apparently conflicting findings. It has been argued that clozapine could induce dopamine blockade and yet manifest its characteristic clinical and pharmacological profile. Bartholini et al. (4) suggested that clozapine may cause a blockade of striatal DA receptors, but this blockade is of the surmountable type in contrast to that produced by cataleptogenic neuroleptics. Snyder, Greenberg and Yamamura (24) suggested that the central DA blocking effect of clozapine is counteracted by its anti-cholinergic properties. This seems unlikely in view of the effects of direct administration of clozapine to the striatum, mentioned above (12) . It has also been shown that administration of clozapine together with physostigmine, a cholinergic drug, still did not induce catalepsy (7) . The hypothesis of differential affinity of clozapine to the different central dopaminergic systems was suggested by Anden and Stock (3) . Clozapine in contrast to haloperidol has only a slight affinity to the (extrapyramidal) striatum, but to a greater degree to the limbic system. Recently, Anden (2) demonstrated that an anticholinergic drug inhibited the neuroleptic-induced increase in DA turnover in the striatum but not in the limbic system. On the basis of this he postulated that neuroleptic-induced extrapyramidal and antischizophrenic effects are due to a functional dopamine deficiency in the corpus striatum and the limbic system respectively. Indeed, Anden and Stock (3) demonstrated that clozapine induces a much higher turnover of dopamine in the limbic cortex than in the striatum.
Further support for the role of dopaminergic systems in the pathogenesis of schizophrenia has come from the demonstration of DA neurons in the limbic cortex (14) . The evidence has been documented and discussed further by Stevens (27) and Torrey and Peterson (25) . More recently, Bunney and Aghajanian (5) also suggested that there may be important pharmacological differences between dopamine receptors associated with the nigrostriatal and mesolimbic dopaminergic systems. They showed that antipsychotic drugs reverse the amphetamine-induced depression of dopamine containing neurons in the midbrain ventral tegmental (VT) area, whereas drugs lacking antipsychotic effects are inactive in this regard. On the other hand, drugs having a high to moderate incidence of extrapyramidal side effects reversed the amphetamine-induced depression of the zona compacta (ZC) cells of the substantia nigra. Clozapine was found to act on the VT cells and not on the ZC cells.
All this tends to support the view that clozapine specifically blocks the dopaminergic receptors of the limbic system. Furthermore, it suggests that the mesolimbic dopamine system may be specifically related to the antipsychotic action of neuroleptic drugs whereas the nigrostriatal system is specifically related to the extrapyramidal side effects.
Conclusion
Clozapine has not invalidated the DA hypothesis of schizophrenia; it has made it more specific. The most valuable contribution of clozapine to medicine may be its demonstration that the capacity to provoke extrapyramidal reactions is not a prerequisite of an effective antipsychotic drug. It also emphasizes the need to revise the screening tests for antipsychotic drugs.
Summary
In this paper we review the results of our clinical evaluation of a novel antipsychotic drug, clozapine, and discuss some fundamental issues in the neuropharmacology of schizophrenia, in the light of the results. Nineteen hospitalized chronic schizo-phrenic patients were treated with clozapine. The drug was administered according to a fixed changing dosage schedule, ranging from 75 mg to 800 mg daily. There was a highly significant improvement as measured by the Brief Psychiatric Rating Scale. At the same time no evidence of Parkinsonism or other extrapyramidal side effects was noted in these patients during the drug administration.
For some time now, drug effect on the extrapyramidal system mediated through the nigrostriatal dopaminergic pathway was considered necessary for therapeutic effects in schizophrenic patients. But the recent discovery of the mesolimbic dopaminergic system raises the possibility that the therapeutic action of antipsychotic drugs could be mediated through this pathway without necessarily affecting the nigrostriatal pathway. This is further supported by the fact that these two dopaminergic systems have somewhat different pharmacological properties in relation to DA turnover and DA receptor blockade.
The present study clearly demonstrates the antipsychotic property of clozapine. It is equally clear that it induces no extrapyramidal effects. These findings tend to support the hypothesis that clozapine may be selectively blocking dopaminergic receptors in the limbic system. The pharmacological evidence from the literature for this selectivity is presented to support the hypothesis that schizophrenic symptoms are related to excessive dopaminergic activity in the limbic system.
In conclusion it can be stated that clozapine represents a significant advance in the investigation of the neuropharmacology and pathophysiology of schizophrenia.
Resume
Dans cet article, on passe en revue les resultats de I'evaluation clinique d'un nouvel agent antipsychotique, la clozapine, et 11 la lumiere de ces resultats, on discute certains problemes fondamentaux relies 11 la neuropharmacologie de la schizophreenie. On traita avec la clozapine dix-neuf schizophrenes chroniques hospitalises. Le medicament fut adrninistre selon une dose variable predeterminee comprise entre 75 et 800 mg par jour. Une amelioration tres significative fut constatee telle que mesuree par l'Echelle Abregee d'Evaluation Psychiatrique. Au cours de la periode d'administration du medicament, on ne remarqua pas d'effets secondaires evidents de type parkinsonien, ni d' autres signes extrapyramidaux.
Depuis assez longtemps, on considerait necessaire pour I' obtention d' effets therapeutiques chez les schizophrenes qu'un neuroleptique exerce, par l'entremise du sentier dopaminergique nigrostrie, une action sur Ie systeme extrapyramidal. Cependant, la recente decouverte du systeme dopaminergique mesol imbique souleve la possibihte que I' action therapeutique de ces medicaments puisse etre exercee par I' intermediaire de ce dernier sentier, sans necessairement affecter celui nigrostrie. Cette possibilite est aussi appuyee par Ie fait que ces deux systemes dopaminergiques ont des proprietes pharmacologiques assez differentes Quant au turnover de la dopamine et au bloc age des recepteurs dopaminergiques.
Cette etude demontre clairement l' activite antipsychotique de la clozapine et I'absence d'induction d'effets extrapyramidaux. Ces resultats tendent done 11 soutenir l' hypothese que la clozapine peut probablement bloquer selectivement les recepteurs dopaminergiques du systerne limbique. Les preuves pharmacologiques emanant de la litterature en faveur de cette selectivite sont presentees en support de I'hypothese que les symptomes schizophreniques sont relies a une activite dopaminergique excessive au niveau du systeme limbique.
On peut conclure que la clozapine constitue un progres significatif pour I' etude de la neuropharmacologie et de la pathophysiologie de la schizophrenie.
